Molecular Partners

Molecular Partners ROA

The Return on Assets (ROA) of Molecular Partners (MOLN.SW) as of Nov 4, 2026 is -60.38 %. In the previous year, Return on Assets (ROA) was -34.09 % — a change of 77.11% (lower).

ROA

-60.38 %

YoY

77.11%

Last updated:

In 2025, Molecular Partners's return on assets (ROA) was -60.38 %, a 77.11% increase from the -34.09 % ROA in the previous year.

The Molecular Partners ROA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROA
Date
ROA
Jan 1, 2018
-23.87 CHF
Jan 1, 2019
-34.58 CHF
Jan 1, 2020
-33.47 CHF
Jan 1, 2021
-36.94 CHF
Jan 1, 2022
44.94 CHF
Jan 1, 2023
-31.25 CHF
Jan 1, 2024
-34.09 CHF
Jan 1, 2025
-60.38 CHF
The Molecular Partners ROA history
YEARROAYoY
-60.38 %+77.11%
-34.09 %+9.09%
-31.25 %-169.54%
44.94 %-221.65%
-36.94 %+10.38%
-33.47 %-3.23%
-34.58 %+44.87%
-23.87 %+35.56%
-17.61 %+74.17%
-10.11 %+14,803.95%
-0.07 %-94.23%
-1.18 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Molecular Partners Stock analysis

What does Molecular Partners do? Molecular Partners AG is a biopharmaceutical company based in Zurich, specializing in the research and development of novel therapies in the fields of cancer and ophthalmology. The company was founded in 2004 as a spin-off from the Swiss Federal Institute of Technology Zurich (ETHZ) and has since made significant progress in drug research and development. The business model of Molecular Partners is based on the development of so-called DARPins (Designed Ankyrin Repeat Proteins). DARPins are artificially created protein molecules that can be used as highly specific binding partners in drug research and development. Due to their modular structure and flexibility, DARPins can bind to a variety of target molecules, thus serving as a basis for the development of new therapies. The various divisions of Molecular Partners focus on the development of therapies in the areas of cancer and ophthalmology. In the field of cancer, the company has a number of promising drug candidates based on DARPins in preclinical and clinical development. One of the most promising candidates is MP0250, a bispecific DARPin that targets two targets and is intended to suppress cancer cell activity. In the field of ophthalmology, Molecular Partners is developing therapies for the treatment of retinal diseases and other eye diseases. One of the most promising candidates in this area is Abicipar, an anti-VEGF DARPin that can be used to treat wet age-related macular degeneration and other retinal diseases. Abicipar has already shown promising results in clinical trials and is currently being submitted for approval to US and European regulatory authorities. Molecular Partners has formed partnerships with leading pharmaceutical and biotech companies such as Amgen, Allergan, Novartis, and Nestlé Health Science to support the development and commercialization of their drug candidates. In addition, the company has entered into a number of licensing and collaboration agreements with other companies to advance the development of new therapies. Overall, Molecular Partners has made significant progress in the development of novel therapies in the fields of cancer and ophthalmology in recent years. The company has developed a unique platform technology on which a variety of therapies can be based, tailored to the specific needs of patients. With its strong partnerships and pipeline of drug candidates, Molecular Partners is well positioned to continue growing and developing new treatment options for patients in the coming years. Molecular Partners is one of the most popular companies on Eulerpool.

ROA Details

Understanding Molecular Partners's Return on Assets (ROA)

Molecular Partners's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Molecular Partners's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Molecular Partners's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Molecular Partners’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Molecular Partners stock

Return on Assets (ROA) of Molecular Partners is -60.38 % in 2025.

Return on Assets (ROA) of Molecular Partners changed from -34.09 % to -60.38 %, representing a 77.11% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Assets (ROA) Molecular Partners since 2006 – with annual values, charts, and detailed analysis.

Return on Assets, also known as ROA, is a financial metric used to measure a company's profitability. It is used to determine how effectively a company uses its assets to generate profits. It is also referred to as the ratio of net income to total assets. ROA is an important indicator of a company's overall financial performance as it measures the company's ability to generate more profit from the assets it employs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Assets (ROA)'s Molecular Partners with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Assets (ROA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Assets (ROA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Molecular Partners

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Molecular Partners